Coya Therapeutics Hosts ALS Drug Development Webinar with Key Experts
Event summary
- Coya Therapeutics to host a webinar on February 17, 2026, focusing on ALS drug development and clinical trial updates.
- Webinar will feature experts Stanley Appel, M.D., and James Berry, M.D., MPH, discussing ALS treatment landscape and Coya’s COYA 302 therapy.
- ALSTARS Phase 2 clinical trial design and enrollment details to be highlighted.
- COYA 302 is a proprietary biologic combination therapy targeting Treg function in ALS patients.
The big picture
Coya Therapeutics is positioning itself as a key player in ALS treatment by leveraging its proprietary Treg-enhancing biologics. The webinar underscores the company’s focus on advancing its ALSTARS Phase 2 trial, which could validate its novel immunotherapy approach in a competitive neurodegenerative disease space. Success here would strengthen Coya’s pipeline and market positioning.
What we're watching
- Clinical Trial Progress
- The pace at which ALSTARS Phase 2 trial enrolls and yields data will determine COYA 302’s viability as an ALS treatment.
- Competitive Positioning
- How Coya’s Treg-focused approach differentiates it from other ALS therapies in development.
- Regulatory Pathway
- Whether COYA 302 can secure Fast Track designation and expedite approval.
Related topics